N-(3-cyclobutyl-5-pyridin-3-ylimidazo[4,5-b]pyridin-2-yl)-3,3-dimethylbutanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(3-cyclobutyl-5-pyridin-3-ylimidazo[4,5-b]pyridin-2-yl)-3,3-dimethylbutanamide
• 化学式: C₂₁H₂₅N₅O
• 分子量: 363.5
• InChiKey: MTHTYAVEEAXGCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  72.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
  申请人：KNOPP BIOSCIENCES LLC

  公开号：US20160031875A1

  公开（公告）日：2016-02-04

  Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

  由公式1表示的化合物可能对Kv7.2/7.3异源多聚体具有强效和/或部分选择性。它们可能在治疗与癫痫、疼痛、神经递质释放等相关的疾病方面有用。
• Kv7 channel activators compositions and methods of use
  申请人：Knopp Biosciences LLC

  公开号：US10851067B2

  公开（公告）日：2020-12-01

  Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

  本文提供了任选取代的苯并咪唑-1,2-基酰胺、包含治疗有效量的此类化合物和药学上可接受的赋形剂的药物组合物，以及用此类化合物和药物组合物治疗 Kv7 相关疾病（如癫痫、肌萎缩侧索硬化症、各种疼痛、过度兴奋、运动障碍、肌张力障碍、躁狂症和耳鸣）的方法。
• IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
  申请人：Knopp Biosciences LLC

  公开号：US20190002464A1

  公开（公告）日：2019-01-03

  Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
• KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
  申请人：Knopp Biosciences LLC

  公开号：US20190284142A1

  公开（公告）日：2019-09-19

  Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
• US9650376B2
  申请人：——

  公开号：US9650376B2

  公开（公告）日：2017-05-16